Frontage offers an impressive suite of services to take lead candidate drugs to the IND stage. With Experimur’s acquisition, Frontage now has significantly expanded our range of services, supporting customers’ drug-development programs beyond IND and into NDA-enabling toxicology studies. Frontage has exceptional bioanalytical supporting capabilities for small molecules, large molecules, and biomarkers.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
At Frontage, we provide comprehensive central lab services, including a range of laboratory testing, histology and pathology services, sample management, and global distribution. See our brochure about next-generation central lab services.
At Frontage, we offer extensive drug metabolism and pharmacokinetic capabilities for new chemical entities and compounds in development. We provide rapid turnaround of high-quality key DMPK data sets to support critical decisions in advancing potential therapeutic agents for further development. Our highly trained scientific staff applies state-of-the-art techniques and best-in-class approaches to provide broad and in-depth expertise/advice to clients on appropriate study designs, execution of studies, and interpretation of the data.
DMPK studies can provide critical data during discovery and development of pharmaceutical and agrochemical products. Frontage’s DMPK services, performed in accredited facilities, can help support lead drug candidate or chemical selection, or help you meet specific regulatory requirements.
At Frontage, we simplify the effort of Investigational New Drug (IND) and reduce the risk by offering all of the critical IND-enabling services required to bring your lead candidate to Phase 1. By providing the right comprehensive end-to-end services, we can accelerate your IND program with the benefit of consistent quality, enhanced efficiency, and optimal cross-functional communications.